• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Premature Ventricular Complexes on Screening Electrocardiogram and Risk of Ischemic Stroke Brief Reports
Conclusions— PVCs are common on routine screening ECGs and are associated with an increased risk of ischemic stroke.
Source: Stroke - April 27, 2015 Category: Neurology Authors: Agarwal, S. K., Chao, J., Peace, F., Judd, S. E., Kissela, B., Kleindorfer, D., Howard, V. J., Howard, G., Soliman, E. Z. Tags: Electrocardiology, Embolic stroke, Epidemiology Brief Reports Source Type: research

Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation Clinical Sciences
Conclusions— Contrary to current guidelines, 30% of patients with atrial fibrillation and recent IS are not prescribed any OAC therapy on discharge, whereas a further 30% are prescribed combination OAC and antiplatelet therapy. Combination OAC and antiplatelet therapy in patients at high cardiovascular risk requires evaluation in clinical trials, particularly with the newer OACs, given their more favorable risk–benefit ratio compared with warfarin.
Source: Stroke - November 24, 2014 Category: Neurology Authors: McGrath, E. R., Kapral, M. K., Fang, J., Eikelboom, J. W., Conghaile, A. O., Canavan, M., O'Donnell, M. J., on behalf of the Investigators of the Ontario Stroke Registry Tags: Secondary prevention, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs Clinical Sciences Source Type: research

Significant Underuse of Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from the China National Stroke Registry
Conclusions: We found that warfarin was significantly underused in patients with known NVAF in China. Age and CHD and prestroke antiplatelet therapy were related factors.
Source: Journal of Stroke and Cerebrovascular Diseases - December 2, 2013 Category: Neurology Authors: Chunjuan Wang, Zhonghua Yang, Chunxue Wang, Yilong Wang, Xingquan Zhao, Liping Liu, David Z. Wang, Hao Li, Yongjun Wang Tags: Original Articles Source Type: research

Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation
Commentary on: Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. Context Historically, the standard medication for stroke prevention in atrial fibrillation (AF) has been a vitamin-K antagonist (warfarin). However, several non-vitamin-K oral anticoagulants (NOACs) have been developed and shown to be at least as effective as dose-adjusted warfarin in their respective phase-3 clinical trials.1–4 These include the direct thrombin inhibitor dabig...
Source: Evidence-Based Medicine - September 15, 2014 Category: Internal Medicine Authors: Steinberg, B. A. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Connective tissue disease, Musculoskeletal syndromes, Diabetes, Arrhythmias Therapeutics Source Type: research

Relation of Left Atrial Dysfunction to Ischemic Stroke in Patients With Coronary Heart Disease (from the Heart and Soul Study)
In conclusion, LA dysfunction is an independent risk factor for stroke or TIA, even in patients without baseline AF.
Source: The American Journal of Cardiology - March 5, 2014 Category: Cardiology Authors: Jonathan M. Wong, Christine C. Welles, Farnaz Azarbal, Mary A. Whooley, Nelson B. Schiller, Mintu P. Turakhia Tags: Arrhythmias and Conduction Disturbances Source Type: research

Antithrombotic therapy for ischaemic stroke patients with AF/RHD in West China daily practice.
CONCLUSION: Our study suggests that overall real-world use of warfarin in IS patients with AF and/or RHD is low before and after admission in West China. Implementation study on this respect should be conducted in this area to improve the daily practice. PMID: 26178783 [PubMed - as supplied by publisher]
Source: Neurological Research - July 17, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Get Rid of Toxins to Reduce Risk of Stroke
Effects of Toxins I’ve been warning you about the toxins in our environment for years. They cause inflammation… They make you gain weight… They cause you to feel fatigued… Our exposure to them starts before we’re even born. One study found 287 chemicals and toxins in the blood of newborn babies.1 It’s shocking. What is in the air we breathe? We breathe in toxins and air pollutants every day. Carbon dioxide, lead, nitrogen oxide, sulfur dioxide, and particulate matter (PM). Causes of Stroke Now, a new study reveals that air pollution is responsible for as many as one-third of all strokes.2 That’...
Source: Al Sears, MD Natural Remedies - July 15, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Health Source Type: news

Stroke Prevention in Atrial Fibrillation: Looking Forward.
Abstract Ischemic strokes related to atrial fibrillation are highly prevalent, presenting with severe neurologic syndromes and associated with high risk of recurrence. Although advances have been made in both primary and secondary stroke prevention for patients with atrial fibrillation, the long-term risks for stroke recurrence and bleeding complications from antithrombotic treatment remain substantial. We summarize the major advances in stroke prevention for patients with atrial fibrillation during the past 30 years and focus on novel diagnostic and treatment approaches currently under investigation in ongoing cl...
Source: Circulation - December 15, 2020 Category: Cardiology Authors: Katsanos AH, Kamel H, Healey JS, Hart RG Tags: Circulation Source Type: research

The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients
Conclusions In a large Canadian AF population, primary care physicians did not provide a stroke or bleeding risk in a substantial proportion of their AF patients. When estimates were provided, they were on the basis of a predictive stroke and bleeding risk index in less than half of the patients. Furthermore, there was under- and overestimation of stroke and bleeding risk in a substantial proportion of patients. As many as 1 in 3 patients receiving warfarin have their TTR < 60%. These findings suggest an opportunity to enhance knowledge translation to primary care physicians.
Source: Canadian Journal of Cardiology - October 23, 2015 Category: Cardiology Source Type: research

Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
We report the case of an elderly patient with permanent AF and coronary heart disease, who had already suffered an ischemic stroke while on warfarin treatment, and was consequently switched to treatment with an association of Rivaroxaban and Aspirin. Her CHA2DS2-VASc score was 9. The patient developed a severe recurrent disabling ischemic stroke. This case goes to show that the novel direct anticoagulants may fail to prevent recurrent stroke in patients at particularly high risk, even when associated with antiplatelet drugs. PMID: 27228488 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - May 27, 2016 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Evaluation of Stroke Incidence with Duty ‐Cycled Multielectrode Phased Radio‐Frequency Ablation of Persistent Atrial Fibrillation Results of the VICTORY AF STUDY
ConclusionsVICTORY AF demonstrated a 1.6% incidence of stroke in PersAF undergoing ablation with a phased RF system which did not meet statistical confidence due to poor enrollment. The secondary outcomes suggest comparable efficacy to phased RF in the TTOP trial. Rigorous clinical evaluation of the stroke risk of new AF ablation technologies as well as restriction to VK ‐antagonist anti‐coagulation appear to be unachievable goals in a clinical multi‐center IDE trial of AF ablation in the current era.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - April 8, 2020 Category: Cardiology Authors: John Hummel, Atul Verma, Hugh Calkins, Lee H. Schwamm, Daryl Gress, Darryl Wells, Joseph Souza, Robert B Hokanson, Lauren Hemingway, Kurt Stromberg, Robert Hoyt, Andrew Wickliffe, David DeLurgio, Lucas Boersma Tags: ORIGINAL ARTICLE Source Type: research

Evaluation of stroke incidence with duty ‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study
ConclusionsVICTORY AF demonstrated a 1.6% incidence of stroke in PersAF undergoing ablation with a phased RF system which did not meet statistical confidence due to poor enrollment. The secondary outcomes suggest comparable efficacy to phased RF in the tailored treatment of permanent AF trial. Rigorous clinical evaluation of the stroke risk of new AF ablation technologies as well as restriction to Vitamin K antagonist anticoagulation appears to be unachievable goals in a clinical multicenter IDE trial of AF ablation in the current era.
Source: Journal of Cardiovascular Electrophysiology - April 23, 2020 Category: Cardiology Authors: John Hummel, Atul Verma, Hugh Calkins, Lee H. Schwamm, Daryl Gress, Darryl Wells, Joseph Souza, Robert B. Hokanson, Lauren Hemingway, Kurt Stromberg, Robert Hoyt, Andrew Wickliffe, David DeLurgio, Lucas Boersma Tags: ORIGINAL ARTICLE Source Type: research

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Publication date: Available online 14 March 2015 Source:The Lancet Author(s): Freek W A Verheugt , Christopher B Granger In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that dire...
Source: The Lancet - March 14, 2015 Category: Journals (General) Source Type: research

Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity Matched Analysis
Conclusions: Compared to warfarin, NOAC use is associated with decreased all‐cause mortality but not stroke risk.  These data from real‐life clinical practice add to existing evidence for decreased mortality among patients prescribed NOACs compared to warfarin.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - July 14, 2015 Category: Cardiology Authors: George Leef, Dingxin Qin, Andrew Althouse, Mian Bilal Alam, Rohit Rattan, Mohamad Bilal Munir, Divyang Patel, Furqan Khattak, Nishit Vaghasia, Evan Adelstein, Sandeep K Jain, Samir Saba Tags: Original Source Type: research

Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity‐Matched Analysis
ConclusionsCompared to warfarin, NOAC use is associated with decreased all‐cause mortality but not stroke risk. These data from real‐life clinical practice add to existing evidence for decreased mortality among patients prescribed NOACs compared to warfarin.
Source: Pacing and Clinical Electrophysiology : PACE - August 7, 2015 Category: Cardiology Authors: GEORGE LEEF, DINGXIN QIN, ANDREW ALTHOUSE, MIAN BILAL ALAM, ROHIT RATTAN, MOHAMAD BILAL MUNIR, DIVYANG PATEL, FURQAN KHATTAK, NISHIT VAGHASIA, EVAN ADELSTEIN, SANDEEP K. JAIN, SAMIR SABA Tags: ORIGINAL Source Type: research

Pages: 1  2  3  4  5  6  7  8